The Kidney Function Puzzle: When Creatinine and Cystatin C Tell Different Stories
.jpg)
One of the little known truths of keeping the NiaHealth dashboard aligned with the latest research is that we can spend weeks combing through the literature, identifying gaps, and synthesizing what’s known, only to have a major new study appear right after we’ve integrated our findings into the NiaHealth lab interpretation system.
It’s the clinical-product version of rain on your freshly washed car.
That’s exactly where we found ourselves just after incorporating the advanced kidney panel, which includes eGFR estimation using both creatinine and cystatin C.
Why eGFR Matters — and Why Creatinine Alone Isn’t Always Enough
eGFR (estimated glomerular filtration rate) is the standard measure used to assess kidney function. In most clinical settings, it is calculated using creatinine — a waste product generated by muscle metabolism — producing the creatinine-based estimate known as eGFRcr.
Accurately estimating kidney function matters because early changes in GFR can signal developing kidney disease. Reduced kidney function is also associated with broader health risks, including cardiovascular disease and mortality.
The challenge is that creatinine is not a perfect marker. Its levels vary significantly depending on muscle mass, diet, and supplements such as creatine. As a result:
- People with high muscle mass or creatine supplementation may appear to have worse kidney function than they actually do.
- People with low muscle mass may appear to have better kidney function than they truly do.
This is where cystatin C becomes valuable.
Cystatin C is a protein produced by all nucleated cells and filtered by the kidneys. Unlike creatinine, its levels are not meaningfully influenced by muscle mass or diet, making it a useful alternative marker for estimating GFR.
Multiple studies have shown that cystatin C based estimates often provide a more accurate assessment of kidney function and can better predict long term health outcomes. The main reason it is not universally used in routine care is cost, since cystatin C testing is more expensive than creatinine.
In line with international guidelines, NiaHealth offers cystatin C as part of our advanced kidney panel. When available, we combine cystatin C with creatinine to calculate eGFRcr-cys, currently the most accurate approach for estimating kidney function.
We also calculate eGFRcr using creatinine alone. Showing both values allows us to identify situations where the two estimates diverge, something that has become an important clinical question in recent years.
The Clinical Puzzle: When eGFR Estimates Don’t Match
Sometimes the combined equation (eGFRcr-cys) produces a value that differs meaningfully from creatinine alone.
When the combined estimate is higher than eGFRcr, interpretation is usually straightforward. Creatinine likely underestimated kidney function because of higher muscle mass or creatine use.
But when the combined estimate is lower than eGFRcr, the interpretation becomes more nuanced.
Cystatin C reflects more than kidney filtration alone. Higher cystatin C levels — which appear as lower eGFRcys or eGFRcr-cys — are also associated with broader physiological stress, including: inflammation, diabetes, obesity, cardiovascular disease, and metabolic aging.
As we saw while developing our NiaAge tool, cystatin C is an independent predictor of morbidity and mortality.
This raised two key questions for our clinical and research teams:
- How large does the discrepancy between eGFRcr and eGFRcr-cys need to be before it becomes clinically meaningful?
- When eGFRcr-cys is substantially lower, how much reflects true kidney impairment versus other factors influencing cystatin C?
We mapped the existing evidence and highlighted the gaps. Around the same time, a new JAMA study addressing this exact issue was published.
What the New JAMA Study Found
The study analyzed data from hundreds of thousands of participants to better understand what happens when creatinine-based and cystatin-C–based eGFR estimates diverge.
Several insights stood out.
Large discrepancies matter.
The researchers defined a clinically meaningful difference as more than a 30 percent gap between eGFRcr and eGFRcys. Individuals whose cystatin-C–based eGFR was substantially lower had significantly higher risks of mortality and cardiovascular events.
Age and comorbidities appear to contribute.
A cystatin-C–based eGFR more than 30 percent lower than eGFRcr was associated with older age, smoking, obesity, and chronic illness.
The combined equation behaves similarly.
Importantly for NiaHealth users, the same patterns were seen when using the combined eGFRcr-cys equation, the approach we use in our platform.
And yet the core ambiguity remains.
Even with this large dataset, the researchers could not fully separate how much of the discrepancy reflects true kidney dysfunction versus non renal factors that influence cystatin C.
In other words, the field is still grappling with the same nuance we have been trying to understand.
This is the nature of biomarker science. Each step forward advances our understanding, while also revealing new questions that require deeper investigation.
What This Means for NiaHealth
Over the last few months, you may have noticed updates to your dashboard if you have had the advanced kidney panel.
Historically, we flagged discrepancies using a simple ±10 mL/min difference between estimates. This approach was intuitive but admittedly somewhat arbitrary.
The new research suggests that a 30 percent relative difference may better represent a clinically meaningful discrepancy and aligns more closely with outcomes based evidence.
Updating our interpretation framework accordingly helps ensure that the insights we deliver reflect the best available science.
What this means for users: if your cystatin-C–based estimate is substantially lower than your creatinine-based estimate, it does not automatically mean kidney disease. But it may signal broader health factors worth understanding more deeply.
Science Moves — and So Do We
There is something both humbling and energizing about moments like this.
You think you have mapped the terrain. Then a new study redraws part of the landscape.
It is a reminder that medicine is always evolving. Our goal is not to reach a point where the science is finished, but to continually integrate new evidence so the insights we deliver remain as accurate and useful as possible for the people we serve.
Our editorial standards & process
At NiaHealth, our mission is to make proactive health possible for all Canadians—by combining science with humanity. We believe that rigorous, evidence-informed health information should never feel out of reach. Every word we publish is intentional. We choose language that empowers rather than overwhelms, clarifies rather than complicates, and respects the lived experiences behind every health question. Learn more here.